FORMULATION AND CHARACTERIZATION OF MONTELUKAST SODIUM MATRIX TABLET

Montelukast sodium is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor. Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit bronchoconstriction due to inhaled LTD 4 in Asthmatics. Doses as low as 5 mg cause substantial blockage of LTD 4 -induced bronchoconstriction. Montelukast biological half life is 2.5 to 5.5 hrs, thereby decreasing bioavailability up to 64%. So in order to improve the bioavailability and efficacy we have designed matrix release tablets. The prepared matrix tablets found to have good precompression and post compression parameters. The swelling performance, release rate features and the in vitro dissolution study. The drug release kinetics from optimized F-5 formulation showed zero order release. The study concludes to retard the release of Montelukast from the tablets. Keywords: Montelukast sodium, HPMC, matrix tablets, sustained release